Marina Kremyanskaya, MD, PhD

In this section, the panel examines how clinical trials and emerging molecular insights may shape the future of polycythemia vera management.

This section provides a balanced overview of currently approved treatments for polycythemia vera, including phlebotomy, hydroxyurea, and interferon.

In this segment the panel challenges the long standing focus on maintaining hematocrit below forty five percent as the sole marker of disease control.

This section examines how emerging agents such as rusfertide and givinostat may reshape the polycythemia vera treatment paradigm.

Experts discuss the place of ruxolitinib for patients with PV resistant or intolerant to hydroxyurea. They note that ruxolitinib can offer durable symptom control and improve hematologic parameters. Benefits include reduction in spleen size, symptomatic relief, and improved quality of life metrics documented in clinical trials. Limitations include potential adverse effects such as weight gain, lipid changes, and infection risk.

The panel reviews current approaches to assessing thrombotic risk. Traditional models focus on age and prior thrombosis history, which provide a foundation for clinical decisions. However, they emphasize that these criteria may not fully capture individual patient risk.

Experts discuss the challenges of managing fatigue and brain fog in patients with polycythemia vera, highlighting new therapies and patient support strategies.

Experts discuss innovative approaches to managing Polycythemia Vera, focusing on improving patient quality of life and treatment outcomes through recent trial insights.

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.